De-escalation of breast radiotherapy after conserving surgery in low-risk early breast cancer patients

被引：22

作者：

Franco, Pierfrancesco ^{[1
]}

Iorio, Giuseppe Carlo ^{[1
]}

Bartoncini, Sara ^{[2
]}

Airoldi, Mario ^{[3
]}

De Sanctis, Corrado ^{[4
]}

Castellano, Isabella ^{[5
]}

Ricardi, Umberto ^{[1
]}

机构：

[1] Univ Turin, Dept Oncol, Radiat Oncol, Via Genova 3, I-10126 Turin, Italy

[2] AOU Citta Salute & Sci, Dept Oncol, Radiat Oncol, Turin, Italy

[3] Univ Turin, Dept Med Sci, Pathol Unit, Turin, Italy

[4] AOU Citta Salute & Sci, Dept Gynecol & Obstet, Breast Unit, Turin, Italy

[5] AOU Citta Salute & Sci, Dept Oncol, Med Oncol 2, Turin, Italy

来源：

MEDICAL ONCOLOGY | 2018年 / 35卷 / 05期

关键词：

De-escalation; Whole-breast radiation; Hypofractionation; Accelerated partial breast irradiation; Boost; Radiotherapy omission; Breast cancer; 20-YEAR FOLLOW-UP; INTERSTITIAL MULTICATHETER BRACHYTHERAPY; TARGETED INTRAOPERATIVE RADIOTHERAPY; HYPOFRACTIONATED RADIATION-THERAPY; RANDOMIZED CLINICAL-TRIAL; LUMPECTOMY PLUS TAMOXIFEN; IN-SITU CARCINOMA; QUALITY-OF-LIFE; LOCAL-CONTROL; NO BOOST;

D O I：

10.1007/s12032-018-1121-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The reduction in the burden related to treatment is becoming more and more important in modern oncology. Radiation therapy is a mainstay option in the postoperative setting for early breast cancer patients after breast-conserving surgery. Nowadays, different options are available to de-escalate radiotherapy in this scenario such as the use of hypofractionated whole-breast radiation, the selective delivery of the boost dose to the lumpectomy cavity, the introduction of accelerated partial breast irradiation and the omission of treatment in appropriately selected patients with low-risk features. We herein provide a review article on this topic.

引用

页数：14

共 75 条

[1]

[Anonymous], B39 NSABP

[2] Hypofractionation with no boost after breast conservation in early-stage breast cancer patients [J].

Arcadipane, Francesca ;

Franco, Pierfrancesco ;

De Colle, Chiara ;

Rondi, Nadia ;

Di Muzio, Jacopo ;

Pelle, Emanuela ;

Martini, Stefania ;

Ala, Ada ;

Airoldi, Mario ;

Donadio, Michela ;

De Sanctis, Corrado ;

Castellano, Isabella ;

Ragona, Riccardo ;

Ricardi, Umberto .

MEDICAL ONCOLOGY, 2016, 33 (10)

[3] Acute Toxicity and Quality of Life of Hypofractionated Radiation Therapy for Breast Cancer [J].

Arsenault, J. ;

Parpia, S. ;

Reiter, H. ;

Doherty, M. ;

Lukka, H. ;

Rakovitch, E. ;

Wright, J. ;

Julian, J. ;

Whelan, T. J. .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03) :S59-S59

[4] Simultaneous integrated boost for adjuvant treatment of breast cancer- intensity modulated vs. conventional radiotherapy: The IMRT-MC2 trial [J].

Askoxylakis, Vasileios ;

Jensen, Alexandra D. ;

Haefner, Matthias F. ;

Fetzner, Leonie ;

Sterzing, Florian ;

Heil, Joerg ;

Sohn, Christof ;

Huesing, Johannes ;

Tiefenbacher, Uta ;

Wenz, Frederik ;

Debus, Juergen ;

Hof, Holger .

BMC CANCER, 2011, 11

[5] Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. [J].

Bartelink, H ;

Horiot, J ;

Poortmans, P ;

Struikmans, H ;

Van den Bogaert, W ;

Barillot, I ;

Fourquet, A ;

Borger, J ;

Jager, J ;

Hoogenraad, W ;

Collette, L ;

Pierart, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (19) :1378-1387

[6] Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer:: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial [J].

Bartelink, Harry ;

Horiot, Jean-Claude ;

Poortmans, Philip M. ;

Struikmans, Henk ;

Van den Bogaert, Walter ;

Fourquet, Alain ;

Jager, Jos J. ;

Hoogenraad, Willem J. ;

Oei, S. Bing ;

Warlam-Rodenhuis, Carla C. ;

Pierart, Marianne ;

Collette, Laurence .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (22) :3259-3265

[7] Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial [J].

Bartelink, Harry ;

Maingon, Philippe ;

Poortmans, Philip ;

Weltens, Caroline ;

Fourquet, Alain ;

Jager, Jos ;

Schinagl, Dominic ;

Oei, Bing ;

Rodenhuis, Carla ;

Horiot, Jean-Claude ;

Struikmans, Henk ;

Van Limbergen, Erik ;

Kirova, Youlia ;

Elkhuizen, Paula ;

Bongartz, Rudolf ;

Miralbell, Raymond ;

Morgan, David ;

Dubois, Jean-Bernard ;

Remouchamps, Vincent ;

Mirimanoff, Rene-Olivier ;

Collette, Sandra ;

Collette, Laurence .

LANCET ONCOLOGY, 2015, 16 (01) :47-56

[8]

Bentzen SM, 2008, LANCET, V371, P1098, DOI 10.1016/S0140-6736(08)60348-7

[9]

Bentzen SM, 2008, LANCET ONCOL, V9, P331, DOI [10.1016/S1470-2045(08)70077-9, 10.1016/S1470-2045(08)60348-7]

[10] Can Interrogation of Tumour Characteristics Lead us to Safely Omit Adjuvant Radiotherapy in Patients with Early Breast Cancer? [J].

Bhattacharya, I. S. ;

Kirby, A. M. ;

Bliss, J. M. ;

Coles, C. E. .

CLINICAL ONCOLOGY, 2018, 30 (03) :158-165

← 1 2 3 4 5 6 7 8 →